Long-acting, locally acting opioid-free gene therapies designed as disease-modifying anti-pain (DMAP) treatments for chronic pain and nervous system disorders. Lead programs target patients with hereditary erythromelalgia (orphan) and chronic knee osteoarthritis pain as non-opioid alternatives.